Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ceDNA vaccine
- Development stage
- Preclinical
- Lead developer
- Generation Bio
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular, Intravenous
01
Overview
ceDNA vaccine is a non-viral genetic medicine platform developed by Generation Bio that utilizes closed-ended DNA (ceDNA) as its genetic payload. Unlike traditional plasmid DNA, ceDNA is a high-capacity, double-stranded, linear construct that is covalently closed, designed to provide stable gene expression without the use of viral vectors. The platform employs a proprietary vaccine-optimized cell-targeted lipid nanoparticle (ctLNP) delivery system to transport the ceDNA into specific cells, such as those in the liver or the immune system. An advanced iteration of this technology, known as immune-quiet DNA (iqDNA), is engineered to minimize detection by the host's innate immune system, thereby potentially increasing the durability and magnitude of the resulting humoral and T-cell responses. Generation Bio has partnered with Moderna to further develop this technology for various therapeutic and prophylactic applications.
- Other names
- closed-ended DNA vaccineimmune-quiet DNA vaccine
Beyond the preview
Go deeper on ceDNA vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ceDNA vaccine.